2009;30:1128 35. S8.1.1-16. Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pres- sure lowering on cardiovascular outcomes in normal weight, over- weight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension. 2010;55:1193 8. S8.1.1-17. Heerspink HJL, Ninomiya T, Perkovic V, et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31:2888 96. S8.1.1-18. Ninomiya T, Zoungas S, Neal B, et al. Efficacy and safety of rou- tine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. J Hypertens. 2010;28:1141 9. S8.1.1-19. Collier DJ, Poulter NR, Dahlof B, et al. Impact of amlodipine- based therapy among older and younger patients in the Anglo- Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). J Hypertens. 2011;29:583 91. S8.1.1-20. Ninomiya T, PerkovicV, Turnbull F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. Blood Pressure Lowering Treatment Trialists' Collaboration. BMJ. 2013;347:f5680. S8.1.1-21. Redon J, Mancia G, Sleight P, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in com- bination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74 83. S8.1.1-22. Ogden LG, He J, Lydick E, et al. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539 43. S8.1.1-23. van der Leeuw J, Visseren FLJ, Woodward M, et al. Predicting the effects of blood pressure-lowering treatment on major cardiovascular events for individual patients with type 2 diabetes mellitus: results fromActioninDiabetesandVascularDisease:PreteraxandDiamicron MR Controlled Evaluation. Hypertension. 2015;65:115 21. 8.1.2. 